Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy

OBJECTIVES: The Lewis-Y antigen is expressed in 44%-90% of breast cancers (BCs). The expression of the antigen in carcinoma tissue differs from that in normal tissues. This study aimed to evaluate the clinical benefit of the humanized anti-Lewis Y monoclonal antibody, hu3S193, in advanced hormone re...

Descripción completa

Detalles Bibliográficos
Autores principales: Testa, Laura, Mano, Max, Arai, Roberto Jun, Bonadio, Renata Colombo, Serrano, Sergio V., Zorzetto, Marina M Costa, Crocamo, Susanne, Smaletz, Oren, Freitas-Junior, Ruffo, Hoff, Paulo M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculdade de Medicina / USP 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478140/
https://www.ncbi.nlm.nih.gov/pubmed/34644735
http://dx.doi.org/10.6061/clinics/2021/e3146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478140/
https://www.ncbi.nlm.nih.gov/pubmed/34644735
http://dx.doi.org/10.6061/clinics/2021/e3146

Ejemplares similares